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Introduction
In most part of the world, Gram-negative bacilli (GNB) are the most frequent microorganisms isolated both from community and nosocomial infections. Among these bacteria, resistance to extended-spectrum cephalosporins (ESCs) has increased over the last decade [1] . In addition, the emergence of CTX-M-type extendedspectrum -lactamases (ESBLs) has modified the epidemiology of ESC resistance in Enterobacteriaceae since the dissemination of ESBL enzymes has occurred in the community as well as in healthcare settings [2] .
The consequence of increasing ESC resistance has been a significant rise in the use of antibiotics active against multidrug-resistant (MDR) bacteria, mainly carbapenems.
Increased carbapenem use has been followed by an increase in carbapenemresistant Pseudomonas aeruginosa and Enterobacteriaceae [1] . The use of carbapenems in intensive care units has been associated with the emergence of imipenem-resistant GNB in the commensal flora, even after a short treatment duration [3] . In addition, new mechanisms of resistance to carbapenems have emerged in the last decade [4] . Therefore, it is in our interest to limit the use of carbapenems to well-defined indications.
We have previously reported a rather high proportion (7.8%) of carbapenem use among patients treated by antibiotics in French hospitals [5] . Hence, a better understanding of the characteristics of carbapenem prescriptions should help to develop comprehensive recommendations for carbapenem use. Therefore, a cross- 
Methods

Study design
Data collection
Healthcare settings had to record data for 10 consecutive inpatients treated by a carbapenem in all wards of the facility, or all inpatients if <10 cases were eligible during the study period. Data collected included prior history of hospitalisation and antibiotic treatment in the previous 3 months, ward hospitalisation and antibiotic received since admission and before the first carbapenem administration.
Data regarding carbapenem treatment (CPR) included the site of infection, empirical versus targeted treatment, reasons for carbapenem initial choice and cessation as recorded by the prescriber, treatment duration, and re-assessment after 2-3 days and 7-10 days. De-escalation was defined as replacement of a carbapenem by 
Statistical analysis
Data were collected using a standardised website questionnaire. Continuous variables were expressed as median and range and were compared using the Kruskal-Wallis test. Categorical variables were expressed as number and proportions, and the  2 test or Fisher's exact test were used as appropriate for comparisons. Statistical analysis was performed using STATA (StataCorp, College Station, TX) and P < 0.05 was deemed statistically significant.
Results
Facilities
A total of 251 healthcare facilities (41 teaching hospitals, 175 non-teaching or private hospitals and 35 rehabilitation or long-term care facilities) participated in the study 
Treatment
The 207 facilities included 2338 patients (62.3% male) receiving at least one CPR (Table 1) , mainly imipenem (n = 2051; 87.7%) and ertapenem (n = 173; 7.4%).
The median age of the patients was 67.0 years (0.1-100.0 years) and 24.5% were aged >80 years. A total of 1485 (63.5%) and 1210 (51.8%) patients had a history of prior hospitalisation and antibiotic treatment, respectively; 1637 patients (70.0%) had a history of one of both of these. A total of 1525 patients (65.2%) already received an antibiotic course (86.7% -lactams) other than a carbapenem since admission and before CPR.
Moreover, 26 patients (1.1%) had CPR on admission, 389 (16.6%) on the day of admission and 975 (41.7%) >10 days after hospital admission. Among the latter, 856
(87.8%) had already been treated by antibiotics since admission (Table 2 ).
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A c c e p t e d M a n u s c r i p t The median duration of CPR was 8 days (1-188 days) and it was longer for the BR group (9 days) than for the EP group (6 days) (P < 0.001). Patients receiving CPR for >10 days (n = 735; 31.4%) were mainly treated for urinary tract infections (26.1%), pulmonary infections (22.3%) and intra-abdominal infections (11.3%).
Among the 141 patients (19.2%) with other infections, 53 (7.2%) had bone and joints infections and 5 (0.7%) had endocarditis. There was no statistical difference in the CPR duration for patients treated for the three main infections with or without AB consultants.
For 1643 patients (70.3%), the carbapenem was combined with at least one antibiotic, and this proportion was higher in the EP group (74.9%) than in the BR group (65.1%) (P < 0.001). However, only 59.8% of the patients received an antibiotic combination active against GNB. The carbapenem was associated with an aminoglycoside in 932 cases (56.7%) and with a fluoroquinolone in 431 cases (26.2%). The median treatment duration with the combined antibiotics was longer in the BR group than in the EP group, either for aminoglycosides (3 days vs. 2 days; P < 0.001) or for fluoroquinolones (11 days vs. 7 days; P < 0.001).
M a n u s c r i p t (Table 3) .
Among the latter, de-escalation was performed in 59 cases (14.9%). The frequency of de-escalation was not different according to the intervention of an AB consultant:
16.6% in case of intervention versus 12.8% without intervention (P = 0.37).
Discussion
We conducted the first countrywide study of carbapenem use at the patient level in a large sample of French hospitals. More than one-half of the CPR was initiated on an empirical basis, including nearly one-half for severe sepsis and one-third for a perceived risk of multidrug resistance. When the CPR choice was based on bacteriological results, an alternate drug was available in more than one-third of cases. Overall, almost one-third of CPR lasted >10 days. Finally, a large part of CPRs were used to treat suspected or confirmed MDR isolates.
This study underlined the long duration of antibiotic treatment in France. There is a lack of data regarding the appropriate duration of antibiotic treatment in most infections. As a consequence, a large majority of guidelines give a range of days for the recommended treatment duration, which does not help in treatment shortening.
However, a large majority of the patients in this study treated for >10 days had M a n u s c r i p t 12 urinary, pulmonary or intra-abdominal infections for which a few studies are now suggesting that antibiotic treatment duration could be shortened [6] .
In the present study, one-third of empirical CPR was initiated in relation to a perceived risk of antibiotic resistance. Such a strategy is widely accepted because low adequacy of initial antibiotic treatment has been linked to an increase in morbidity and mortality in severe sepsis. The dramatic increase in gastrointestinal carriage of ESBL-producing Enterobacteriaceae in the community reinforces this strategy [2] . The fact that ESBL-EB infections remain infrequent among colonised patients [7, 8] and that widespread screening for ESBL-EB carriage could lead to inappropriate use of carbapenems [9] should question this strategy in the context of carbapenem resistance emergence.
We reported that 16.9% of EP patients did not have any microbiological sample drawn and that 31.3% had sterile microbiological samples. Hence, approximately one-half of the patients receiving empirical CPR in French healthcare settings were without positive bacteriological results, suggesting that the use of a carbapenem was based on a perception of the risk of resistance. Of interest, CPR duration was similar among patients without and those with microbiological results. These results contradict with the fact that all facilities declared having an AB consultant and that a large majority declare controlling carbapenem dispensing and having a systematic re-assessment of prescription, strategies that have been proven to be efficient [10] .
In cases where empirical use of large-spectrum antibiotics is considered as good practice, de-escalation is a required partner. In this study, de-escalation was clearly Escherichia coli bacteraemia [11, 12] . Nevertheless, generalisation of the latter observational studies is difficult because source of infection, severity of illness and antibiotic dosage may play a major role in treatment outcome [13] . In addition, it has been suggested that the minimum inhibitory concentration (MIC) of -lactams combined with inhibitors may be of interest only for bloodstream infections with nonurinary tract sources [14] . Finally, the choice of antibiotics based on MIC levels is not implementable when considering empirical treatment. Hence, carbapenems will remain the initial choice for empirical treatment of serious life-threatening infections when MDR organisms are suspected [12] . In such cases, and as shown in this study, AB consultants may help in achieving de-escalation. Hence, antimicrobial stewardship programmes should place the de-escalation issue as a priority [10] .
This study has some limitations. First, alternatives to carbapenems were defined solely on AST results. We did not consider other parameters involved in the antibiotic choice, such as primary site and severity of infection, bacterial load and antibiotic MIC. Second, we did not consider ertapenem as de-escalation, in contrast to other studies. However, there is no consensus regarding the definition of de-escalation
[15] and only a small number of patients received ertapenem as second carbapenem, which is likely not to impact the results. Third, the study was performed A c c e p t e d M a n u s c r i p t 24 a Data are given as n (%).
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